Get started
Author

Vincent Bourgeois

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
2022 · Thierry Conroy, Florence Castan, et al. · JAMA Oncology · 385
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
2021 · Jean marc Phelip, Jérôme Desrame, et al. · Journal of Clinical Oncology · 141
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
2017 · T. Walter, D. Tougeron, et al. · European Journal of Cancer · 114
Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study
2020 · Marie Selvy, Bruno Pereira, et al. · Journal of Clinical Medicine · 76
PDF
Relative contribution of Ki-ras gene analysis and brush cytology during ERCP for the diagnosis of biliary and pancreatic diseases
1998 · Jean-Luc Van Laethem, Vincent Bourgeois, et al. · Gastrointestinal Endoscopy · 69
The Place of Upper Gastrointestinal Tract Endoscopy Before and After Vertical Banded Gastroplasty for Morbid Obesity
1997 · D. Verset, J.-J. Houben, et al. · Digestive Diseases and Sciences · 68
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
2018 · Jean-Marc Phelip, Julien Edeline, et al. · Digestive and Liver Disease · 54
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
2021 · Jean-Frédéric Blanc, Faiza Khemissa, et al. · Hepatology International · 51
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
2018 · Thomas Aparicio, Michel Ducreux, et al. · European Journal of Cancer · 46
PDF
Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis
2016 · C. Baldini, A. Escande, et al. · Pancreatology · 45
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
2024 · Alessandro Parisi, Blandine Delaunay, et al. · European Journal of Cancer · 28
PDF
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
2020 · Yves Rinaldi, Anne-Laure Pointet, et al. · European Journal of Cancer · 21
PDF
Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial
2024 · Antoine Adenis, Arlette Da Silva, et al. · EClinicalMedicine · 17
52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial
2020 · J.M. Phelip, J. Desrame, et al. · Annals of Oncology · 14
PDF
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX ‐bevacizumab failure for COlorectal cancer ( BEFLICO ): An AGEO multicenter study
2022 · Cécile Torregrosa, Simon Pernot, et al. · International Journal of Cancer · 12
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
2022 · Emilie Hafliger, Alessandra Boccaccino, et al. · European Journal of Cancer · 12
PDF
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy
2021 · Nicolas Kerckhove, Marie Selvy, et al. · Frontiers in Pharmacology · 12
PDF
Idiopathic colonic varices: an unusual cause of massive lower gastrointestinal hemorrhage.
2000 · M Van Gossum, K Reuss, et al. · PubMed · 12
STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.
2022 · Benoist Chibaudel, Louis-Marie Dourthe, et al. · Journal of Clinical Oncology · 11
Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life
2024 · David Balayssac, Nicolas Kerckhove, et al. · Supportive Care in Cancer · 10
PDF
Results of the Phase II randomized French trial PRODIGE 21 comparing sorafenib vs pravastatin vs sorafenib and pravastatin vs best supportive care for the palliative treatment of HCC in CHILD B cirrhotic patients
2018 · J.-F. Blanc, F. Khemissa, et al. · Journal of Hepatology · 9
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
2026 · Philippe Merle, Jean-Frederic Blanc, et al. · The Lancet. Gastroenterology & hepatology · 6
FOLFIRIChemotherapy in Patients with Advanced Non Resectable Esophageal or Junctional Adenocarcinoma: A Pilot Study
2011 · C. Ferte, O. Romano, et al. · Journal of Chemotherapy · 5
Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study
2025 · M. Koopman, R. Garcia-Carbonero, et al. · ESMO Gastrointestinal Oncology · 3
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).
2024 · Philippe Merle, Jean-Marie Peron, et al. · Journal of Clinical Oncology · 3
Works count: 56
Citation count: 1,254
H-index: 14
I10-index: 20
Year
Topic
Type